- Home
- CBRL vs AUPH Comparison
CBRL vs AUPH Comparison
Compare CBRL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRL
- AUPH
- Stock Information
- Founded
- CBRL 1969
- AUPH 1993
- Country
- CBRL United States
- AUPH Canada
- Employees
- CBRL N/A
- AUPH N/A
- Industry
- CBRL Restaurants
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CBRL Consumer Discretionary
- AUPH Health Care
- Exchange
- CBRL Nasdaq
- AUPH Nasdaq
- Market Cap
- CBRL 1.2B
- AUPH 1.1B
- IPO Year
- CBRL N/A
- AUPH 1999
- Fundamental
- Price
- CBRL $59.21
- AUPH $7.78
- Analyst Decision
- CBRL Hold
- AUPH Strong Buy
- Analyst Count
- CBRL 8
- AUPH 2
- Target Price
- CBRL $53.86
- AUPH $11.50
- AVG Volume (30 Days)
- CBRL 1.2M
- AUPH 1.1M
- Earning Date
- CBRL 06-05-2025
- AUPH 07-31-2025
- Dividend Yield
- CBRL 1.69%
- AUPH N/A
- EPS Growth
- CBRL N/A
- AUPH N/A
- EPS
- CBRL 2.58
- AUPH 0.27
- Revenue
- CBRL $3,510,062,000.00
- AUPH $247,295,000.00
- Revenue This Year
- CBRL $1.88
- AUPH $12.15
- Revenue Next Year
- CBRL $1.81
- AUPH $18.31
- P/E Ratio
- CBRL $22.89
- AUPH $29.77
- Revenue Growth
- CBRL 2.84
- AUPH 29.20
- 52 Week Low
- CBRL $33.86
- AUPH $5.20
- 52 Week High
- CBRL $65.43
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- CBRL 56.84
- AUPH 41.71
- Support Level
- CBRL $51.95
- AUPH $7.81
- Resistance Level
- CBRL $60.68
- AUPH $8.29
- Average True Range (ATR)
- CBRL 3.31
- AUPH 0.18
- MACD
- CBRL -0.17
- AUPH -0.03
- Stochastic Oscillator
- CBRL 71.16
- AUPH 11.11
About CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The restaurants of the company are open for breakfast, lunch, and dinner, with menus that offer home-style country food. The company generates maximum revenue from the Restaurants.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.